Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 900 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $44.50, for a total value of $40,050.00. Following the transaction, the director directly owned 3,595,986 shares of the company’s stock, valued at $160,021,377. The trade was a 0.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $38,928.75.
• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $4,449.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Price Performance

SION opened at $42.37 on Friday. The firm has a market capitalization of $1.89 billion and a P/E ratio of -8.70. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00. The company has a fifty day moving average price of $38.80 and a 200-day moving average price of $27.25.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Institutional Trading of Sionna Therapeutics

A number of hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. purchased a new stake in shares of Sionna Therapeutics in the 3rd quarter worth about $30,000. BNP Paribas Financial Markets bought a new stake in Sionna Therapeutics during the second quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Sionna Therapeutics during the second quarter worth about $45,000. Virtus Investment Advisers LLC purchased a new stake in Sionna Therapeutics in the second quarter worth about $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Sionna Therapeutics during the second quarter valued at approximately $117,000.

Analysts Set New Price Targets

SION has been the topic of a number of recent analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Jones Trading assumed coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday. BTIG Research began coverage on Sionna Therapeutics in a research note on Wednesday, November 19th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.33.

Trending Headlines about Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Senior insiders and institutional holders still retain very large stakes (reported holdings ~3.596M shares each, valued ~ $160M), which signals continued alignment with long‑term performance and limits the risk of a meaningful shift in control. SEC filing
• Negative Sentiment: Director Peter A. Thompson sold a total of 1,875 SION shares across Dec. 17–19 at an average price ~ $44.49–44.50 (proceeds ≈ $83.4k). Each sale is small relative to his stake (ownership dipped ~0.03%), but the filings can prompt negative short‑term sentiment. SEC filing
• Negative Sentiment: OrbiMed Advisors LLC (reported as a director-level holder) executed the same pattern of sales (875, 100 and 900 shares on Dec. 17–19) at similar prices, reducing its position by ~0.02–0.03%. Like the individual sales, the absolute size is small versus the owner’s remaining stake but likely contributes to today’s downside pressure. SEC filing

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.